Overview

Mitoxantrone Hydrochloride Liposome Injection in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Status:
Not yet recruiting

Trial end date:
2025-09-30

Target enrollment:

Participant gender:

Summary

A multicenter, single-arm, phase 2 study of mitoxantrone hydrochloride liposome injection in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

Phase:

Phase 2

Details

Lead Sponsor:

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Treatments:

Mitoxantrone